ALL PSYCHEDELIC AND PSYCHEDELIC STOCK NEWS

PSYCHECEUTICAL TO CONDUCT THE FIRST EVER PHASE I AND II CLINICAL TRIALS OF A NOVEL KETAMINE TOPICAL CREAM TO TREAT PTSD

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia

The Kahner Global Cannabis & Psychedelics Investment Summit.

Kahner Global’s 8th annual Cannabis & Psychedelics Investment Summit  When:...

Awakn Life Sciences (AWKNF) $0.30 Announces Signing of Lease for Second Clinic in Norway.

Trondheim in central Norway will be the location of Awakn's 4th clinic LIVE QUOTE

Silo Pharma (SILO) Issues Letter to Shareholders

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine LIVE QUOTE

Silo Pharma (SILO) $3.36 Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

View Post ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...

Stressed Wall Street Execs Flock to Ketamine Therapy Sessions (NY Post)

Therapy’s a trip for these Wall Street executives. Wealthy stock traders are flocking to a Manhattan-based ketamine therapy practice that doles out...

Silo Pharma (SILO) Attends Dawson James Conference.

We watched an excellent presentation from management at the Dawson conference and starting our due diligence now....

‘Magic Mushroom’ Psychedelic may Help Heavy Drinkers Quit (AP News)

Psychedelic Drug Helped People with Alcohol use Disorder Reduce Drinking, Study Shows (Today) Psilocybin,...

Stan Grof, Psychedelic’s Elder Statesman.

Stan Grof — Lessons from ~4,500 LSD Sessions and Beyond https://youtu.be/3mdYUmvTeig PLAYLIST

PharmaTher (PHRM, PHRRF) $0.10 Gets $3.80 Price Target From H.C. Wainwright – 37 Times (3,700%) Higher.

Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase...

Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.

MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...

Australian Icannex (IHL:ASX) Headed to NASDAQ?

Incannex completes Phase 2 trial for its cannabinoid drug for sleep apnea, flags Nasdaq listing in 2022

Testimonial: The Ibogaine Clinic, Playa Del Carmen

VIDEO TESTIMONIALS https://youtu.be/hrrLoxuR2oo VISIT WEBSITE

KetaDash

Ketamine at Home Treatments
RESEARCH

Most Popular

PSYCHECEUTICAL TO CONDUCT THE FIRST EVER PHASE I AND II CLINICAL TRIALS OF A NOVEL KETAMINE TOPICAL CREAM TO TREAT PTSD

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia

The Kahner Global Cannabis & Psychedelics Investment Summit.

Kahner Global’s 8th annual Cannabis & Psychedelics Investment Summit  When:...

Awakn Life Sciences (AWKNF) $0.30 Announces Signing of Lease for Second Clinic in Norway.

Trondheim in central Norway will be the location of Awakn's 4th clinic LIVE QUOTE

LARGE CAP PSYCHEDELIC STOCKS

PSYCHEDELIC FUNDS AND ETFS